PSC
Patient Square Capital Portfolio holdings
AUM
$467M
1-Year Est. Return
175.86%
This Fund
S&P 500
1 Year Est. Return
+175.86%
AUM
$374M
AUM Growth
+$96.5M
(+35%)
Holding
27
Top Buys
| 1 | +$9.31M | |
| 2 | +$6.76M | |
| 3 | +$4M | |
| 4 |
Dianthus Therapeutics
DNTH
|
+$3.19M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$2.98M |
Top Sells
| 1 | +$13.4M | |
| 2 | +$8.9M | |
| 3 | +$6.54M | |
| 4 |
Scholar Rock
SRRK
|
+$5.45M |
| 5 |
Insmed
INSM
|
+$3.97M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$19.9B
| $189M | 50.51% |
12,480,000
|
|
||
|
2
Insmed
INSM
$31B
| $47M | 12.57% |
326,400
-32,400
|
|
||
3
EyePoint Inc
EYPT
$1.15B
| $14.4M | 3.85% |
1,011,839
-340,998
|
|
||
|
ABVX
4
Abivax
ABVX
$9.73B
| $12.9M | 3.45% |
+151,833
|
|
||
|
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
| $11.6M | 3.1% |
121,000
+106,000
|
|
||
6
argenx
ARGX
$42.4B
| $11.4M | 3.06% |
15,500
-13,500
|
|
||
7
Liquidia Corp
LQDA
$3.29B
| $9.1M | 2.43% |
400,000
-620,000
|
|
||
8
Pharvaris
PHVS
$1.7B
| $8.62M | 2.31% |
345,381
+101,098
|
|
||
9
Ocular Therapeutix
OCUL
$1.8B
| $8.36M | 2.24% |
715,000
-102,699
|
|
||
10
Mirum Pharmaceuticals
MIRM
$5.47B
| $7.64M | 2.04% |
104,262
-9,200
|
|
||
11
Agios Pharmaceuticals
AGIO
$1.64B
| $5.37M | 1.44% |
133,827
-5,905
|
|
||
12
Kymera Therapeutics
KYMR
$6.5B
| $5.24M | 1.4% |
92,592
-47,408
|
|
||
13
Enliven Therapeutics
ELVN
$1.8B
| $5.13M | 1.37% |
250,838
+5,000
|
|
||
14
Celcuity
CELC
$5.23B
| $4.94M | 1.32% |
+100,000
|
|
||
|
15
Dianthus Therapeutics
DNTH
$3.46B
| $4.92M | 1.32% |
+125,000
|
|
||
16
Disc Medicine
IRON
$2.26B
| $4.89M | 1.31% |
74,000
|
|
||
17
uniQure
QURE
$954M
| $4.38M | 1.17% |
+75,000
|
|
||
|
18
Amylyx Pharmaceuticals
AMLX
$1.55B
| $4.3M | 1.15% |
+316,312
|
|
||
19
Nurix Therapeutics
NRIX
$1.53B
| $4.04M | 1.08% |
437,237
+24,941
|
|
||
20
Allogene Therapeutics
ALLO
$499M
| $3.7M | 0.99% |
2,981,396
+346,396
|
|
||
21
Assembly Biosciences
ASMB
$435M
| $3.46M | 0.93% |
+135,182
|
|
||
22
Avalo Therapeutics
AVTX
$263M
| $1.27M | 0.34% |
+100,000
|
|
||
23
Perspective Therapeutics
CATX
$524M
| $1.2M | 0.32% |
+349,323
|
|
||
24
Geron
GERN
$993M
| $1.16M | 0.31% |
845,000
+129,000
|
|
||
25
Cullinan Oncology
CGEM
$792M
| – | – |
-868,897
|
|